JPRN-UMIN000006445已完成未知
Observational study of serum HER2 in HER2 positive advanced gastric cancer treated with trastuzumab in combination with capecitabine plus cisplatin(XP+H) - SHERLOCK2 Trial
Sapporo Medical University 1st department of Internal Medicine0 个研究点目标入组 10 人开始时间: 2011年9月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Other malignancies within the last 2 years, except for carcinoma in situ or basal cell carcinoma 2)Positive serum pregnancy test in women of childbearing, or lactating women 3)History of psychiatric disability judged by investigator to be clinically significant, precluding informed consent. 4)Serious intercurrent infections 5)Patients whom physician determines as inappropriate
研究者
相似试验
已完成
不适用
Observational study of Serum HER2 in HER2 negative advanced gastric cancer treated with capecitabine plus cisplatin(XP)Gastric cancerJPRN-UMIN000006442Sapporo Medical University 1st department of Internal Medicine50
招募中
不适用
Multicenter study of serum HER2 monitoring in tissue HER2 positive gastric cancerAdvanced gastric cancerJPRN-UMIN000013186Gastroenterologic Surgery, Kanazawa University30
已完成
不适用
Observational study of HER2 positive rate in advanced or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-UMIN000006190Japanese Foundation for Multidisciplinary Treatment of Cancer1,200
进行中（未招募）
1 期
DetectIV - Treatment of patients with advanced metastatic breast cancer and circulating blood cells devoid of Her2/neu.EUCTR2013-001269-18-DEniversitätsklinikum Ulm (AöR)300
招募中
不适用
A study for assessment of HER2 status using Gene-Protein Assay (GPA) in metastatic colorectal cancercolorectal cancerJPRN-UMIN000039751ational Cancer Center150